ESC 23: Hot Line & Late-breaking Science Video Collection
Published: 04 August 2023
-
Views:
5039 -
Likes:
7
-
Views:
5039 -
Likes:
7
-
Up Next
-
9m 37sPart 2 | Session 3 The RECORD MI Registry
-
30m 23sPart 2 | Session 4 Heart Failure at ESC 2023: Recapitulations, Postulations, Predictions
-
13m 28sPart 3 | Session 1 Day 1 Highlights: New Guidelines, STEP-HFpEF, COP-AF
-
16m 34sPart 3 | Session 2 Day 2 Highlights: BUDAPEST-CRT, FIRE, ECLS-Shock, STOPDAPT-3
-
13m 51sPart 3 | Session 3 Day 3 Highlights: OCT Trials, MULTISTARS-AMI, ATTRibute-CM
-
8m 3sPart 3 | Session 4 Day 4 Highlights: OPT-BIRISK & NITRATE-CIN
-
6m 46sPart 4 | Session 1 New Guidelines For the Management of Acute Coronary Syndromes
-
3m 42sPart 4 | Session 2 NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE
-
3m 42sPart 4 | Session 3 LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients
-
6m 14sPart 4 | Session 4 Economic Burden of Cardiovascular Disease in the EU
-
3m 22s
-
4m 1s
-
3m 59sPart 4 | Session 7 HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency
-
4m 49sPart 4 | Session 8 SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation
-
4m 41s
-
4m 12sPart 4 | Session 10 ILUMIEN IV: OCT Vs Angiography
-
5m 20sPart 4 | Session 11 ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure
-
5m 23sPart 4 | Session 12 MULTISTARS AMI: Immediate Vs Staged PCI in STEMI and MVD
-
6m 3sPart 4 | Session 13 OCT Vs IVUS Vs Angiography Guidance
-
4m 5sPart 4 | Session 14 OCTOBER: OCT-Guided or Angiography-Guided PCI in Complex Bifurcation Lesions
-
2m 55sPart 4 | Session 15 DANPACE II: Reducing Atrial Pacing in Sinus Node Disease
-
6m 43sPart 4 | Session 16 COP-AF: Colchicine for Perioperative AF
-
4m 33sPart 4 | Session 17 CASTLE-HTx: Catheter Ablation for AF in Pts with Heart Failure
-
4m 53sPart 4 | Session 18 OCTIVUS: OCT Vs IVUS-Guided Percutaneous Coronary Intervention
-
4m 56sPart 4 | Session 19 PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure
-
4m 16s
-
4m 8sPart 4 | Session 21 ONCO DVT: Optimal Duration of DOAC Therapy for IDDVT Patients with Cancer
-
4m 39sPart 4 | Session 22 ATTRibute-CM Trial
-
5m 21sPart 4 | Session 23 RIGHT: Post-PPCI Anticoagulation in STEMI Patients
-
6m 1sPart 4 | Session 24 ARAMIS: Anakinra versus Placebo in Acute Myocarditis
-
4m 9s
-
6m 42sPart 5 | Session 1 Takeaways from ESC 2023 with Dr Cvijic & Dr Grapsa
-
9m 47sPart 5 | Session 2 Takeaways from ESC 2023 with Dr Al-Lamee, Dr Colleran & Dr Paradies
-
3m 33sPart 6 | Session 1 Leadership in Guidelines and Cardiovascular Education with Dr Robert Byrne
-
59sPart 6 | Session 2 Patient Care and Treatment Strategies with Dr Myeong-Ki Hong
-
2m 2s
-
1m 27sPart 6 | Session 4 Intersection of Politics and Medicine with Dr Luengo-Fernandez
-
1m 24sPart 6 | Session 5 Choosing Cardiology and Advice to Researchers with Dr Robert Mentz
-
1m 10sPart 6 | Session 6 Leadership in the Context of Clinical Trials with Dr Michelle O'Donoghue
-
46sPart 6 | Session 7 Trials to Watch Out For with Dr Masahiro Natsuaki
-
49s
-
1m 2sPart 6 | Session 9 Emerging Topics in Electrophysiology with Dr Tobias Reichlin
-
1m 23sPart 6 | Session 10 Key Trials and Data from ESC 23 with Dr Ziad Ali
-
36s
-
58sPart 6 | Session 12 Inspiring Teams with Prof Barbara Stahli
-
2m 21sPart 6 | Session 13 Advice for Early-Career Researchers from Dr Gregg Stone
-
48sPart 6 | Session 14 New Technologies in Electrophysiology with Dr Mads Brix Kronborg
-
1m 25sPart 6 | Session 15 Considering Unmet Needs in Patient Care with Dr Duk-Woo Park
-
59sPart 6 | Session 16 Improving Clinical Practice with Dr Do-Yoon Kang
-
1m 28sPart 6 | Session 17 Contributing to the Guidelines with Dr Jozine Ter Maaten
-
2m 41sPart 6 | Session 18 Emerging Trends in Amyloidosis with Prof Julian Gillmore
-
30sPart 6 | Session 19 Working With Role Models with Dr Yan Yan
-
1m 17sPart 6 | Session 20 The Importance of Mentorship with Dr Giles Montalescot
-
1m 24sPart 6 | Session 21 Personalised Medicine & Team Approach With Dr Christian Sohns
-
1m 51sPart 6 | Session 22 Advancement of EP & Adapting New Approaches With Dr Philipp Sommer
-
2m 14s
-
47m 55sPart 1 | Session 1 ESC 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 31sPart 1 | Session 2 ESC 23 Late-breaking Science Preview Joost Daemen, Nicolas M Van Mieghem
-
13m 31sPart 2 | Session 1 The ECLS-Shock Trial Harriette Van Spall, Holger Thiele
Overview
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
- Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
- Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
- We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Daily Wrap-Ups with Dr Alasnag & Dr Al-Shaibi
Part 4
Expert Interviews
Part 5
Women as One & Radcliffe Cardiology Presents
Part 6
Behind the Heart
About the episode
ESC 23 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial.
Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with obesity-related HFpEF have a high burden of debilitating symptoms and physical limitations, leading to a poor quality of life.
Semaglutide is a GLP-1 receptor antagonist, which has been shown to substantially produce weight loss in people who are overweight and obese. STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. 592 patients were randomized to receive once-weekly semaglutide 2.4mg or placebo for 1 year.
The trial met both primary endpoints, showing a mean change in body weight of -13.3% with semaglutide, and a change in KCCQ-CCS of 16.6 points from baseline to week 52.
Recorded on-site at ESC Congress 2023, Amsterdam.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Comments